Life Sciences runs on data. From high complexity omics data through to validatory assays, from clinical trials patient data through to sales and manufacturing. It is an asset and a resource that every organization relies on.
Producing high value data is likely to facilitate easier budget discussions for funding for research. Being able to show the financial value to potential investors/board members or stock holders can only improve forecasts and company value.
Why then does it often get missed from the financial balance sheet?
Seen as an intangible it is, by it’s very nature, hard to value. In this whitepaper, we suggest formulae to allow the consistent valuation of your data to help ensure that the financial potential it holds is measured, considered and available for your business planning activities.
Download the guide, read it, enjoy it and share it.
Regards,
The Genestack team